Idorsia.com
  • Home
  • About Idorsia
    • Idorsia today
      • Our strategy
      • Our drug discovery approach
      • Our pipeline
      • Our locations
      • History
    • Idorsia people
      • Our organization
      • Our behaviors
      • Leaders
      • Board of Directors
    • Target diseases
      • Fabry disease
      • Insomnia
      • Cerebral vasospasm
      • Resistant Hypertension
      • Lupus
      • AMI
    • Partnerships
  • Our responsibilities
    • Our Approach
    • Ethics
    • Quality
    • Governance
      • Internal organization of the Board
      • Compensation governance
      • Policies & Charters
    • Our Employees
    • Serving Patients
    • Environment
    • Our Communities
  • Investors
    • Results Day Center
    • Our equity story
      • Company strategy
      • Development Pipeline
      • Corporate Governance & Sustainability
    • Financial information
      • Financial overview
      • Company funding
      • Financial archive
    • Corporate Reports
    • News & Events
      • Media releases
      • J.P. Morgan Healthcare Conference 2022
      • Annual General Meeting
      • Pipeline webcasts
      • Financial reporting webcasts
    • Stock information
      • Stock overview
      • Stock chart tool
      • Covering analysts
      • Consensus estimate
  • Media
    • News archive
    • Media center
    • Social media
    • Resources in German
  • Careers
    • Working@Idorsia
      • Recruitment, Development & Retention
      • Diversity & Inclusion
      • Recognition
      • Compensation principles
      • Health, Safety & Well-being
    • Job opportunities
    • Living in Basel
    • FAQ
      • Privacy policy
  • Contact
  • Idorsia today
    • Our strategy
    • Our drug discovery approach
    • Our pipeline
    • Our locations
    • History
    • Our strategy
    • Our drug discovery approach
    • Our pipeline
    • Our locations
    • History
  • Idorsia people
    • Our organization
    • Our behaviors
    • Leaders
    • Board of Directors
    • Our organization
    • Our behaviors
    • Leaders
    • Board of Directors
  • Target diseases
    • Fabry disease
    • Insomnia
    • Cerebral vasospasm
    • Resistant Hypertension
    • Lupus
    • AMI
    • Fabry disease
    • Insomnia
    • Cerebral vasospasm
    • Resistant Hypertension
    • Lupus
    • AMI
  • Partnerships
Follow us:
Viewing options

This website is subject to the terms and conditions outlined in the legal and privacy statement.

Last update: 15.01.2022

Legal & privacy statement|Site map|Cookie policy|Webmaster

Copyright © 2022 Idorsia Pharmaceuticals Ltd